Northbrook, IL 60062 -- (SBWIRE) -- 12/20/2023 -- ELISpot and FluoroSpot Assay Market in terms of revenue was estimated to be worth $ 292 million in 2023 and is poised to reach $ 421 million by 2028, growing at a CAGR of 7.6% from 2023 to 2028 according to a new report by MarketsandMarkets.

The growth of this market is majorly due to by Increasing use of ELISpot and FluoroSpot assays in the field of malignancy. However, Dearth of skilled professionals is one of the challenges for which may hinder the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584

Browse in-depth TOC on "ELISpot and FluoroSpot Assay Market"
207 - Tables
47 - Figures
232 - Pages

EliSpot Assay kits in the kits product segment to witness the highest shares during the forecast period.

Based on the product, Based on the product, the ELISpot and FluoroSpot Assays Market is classified into Assay Kits (By Technique - ELISpot Assay Kits, FluoroSpot Assay Kits., By Utility - Research Kits, Diagnostic Kits., By Analyte - T-cell-based Kits, B-cell-based Kits, Other Analyte Kits), Analyzers, Ancillary Products. The EliSpot Assay kits, segment is expected to dominate because of its wider application Assay kits typically offer a user-friendly and convenient solution for researchers and laboratories. They often come with pre-packaged reagents and standardized protocols, simplifying the assay process. Likewise, assay kits can be designed to cater to a wide range of users, from experienced researchers to those with less specialized expertise. This accessibility broadens the market and increases the adoption of EliSpot and FluoroSpot assays.

US dominates the North American ELISpot and FluoroSpot Assays Market

Based on the North America region, the ELISpot and FluoroSpot Assays Market is divided into US and Canada. US is expected to dominate the ELISpot and FluoroSpot Assays Market. The United States has a highly advanced and sophisticated healthcare infrastructure, including research facilities, laboratories, and healthcare institutions. This infrastructure supports the development, adoption, and implementation of advanced diagnostic technologies such as EliSpot and FluoroSpot assays. Similarly, The U.S. is a global hub for biomedical research and innovation. The presence of leading research institutions, academic centers, and biotechnology companies fosters a conducive environment for the development and validation of novel diagnostic as well as research assays.

China dominates the Asia Pacific ELISpot and FluoroSpot Assays Market

The APAC ELISpot and FluoroSpot Assays Market is segmented into Japan, China, India, and Rest of Apac. In 2023, China accounted for the largest share of the Asian ELISpot and FluoroSpot Assays Market. The large share of China can be attributed to the economic growth in the country, the increasing incidence of chronic diseases and the rising focus on vaccine development and cancer research, growth in the geriatric population, and favourable government support.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=124350584

ELISpot and FluoroSpot Assay Market Dynamics:

Drivers:

- Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
- Increasing vaccine development to address challenges of antimicrobial resistance
- Increasing use of ELISpot and FluoroSpot assays in oncology
- ELISpot assays as diagnostic tool in drug hypersensitivity reaction
- Growth in biotechnology and biopharmaceutical industries

Restraints:

- Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables
- High cost of assays kits and analyzers

Opportunities:

- Use of FluoroSpot assays for multiple-analyte detection in single well

Challenge:

- Availability of alternative detection technologies
- Dearth of skilled professionals

Key Market Players of ELISpot and FluoroSpot Assay Industry:

The major players in the ELISpot and FluoroSpot Assays Market are Oxford Immunotec USA, Inc. (Subsidiary of Revvity Inc.) (UK), Becton, Dickinson and Company (BD) (US), Cellular Technology Limited (CTL) (US), Mabtech (Sweden), Abcam plc. (UK), Bio-Techne (US), Merck KGaA (Germany), Autoimmun Diagnostika GmbH (Germany), and U-CyTech (Netherland)

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World – 12%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=124350584

Recent Developments:

- In 2022, The company Mabtech (Sweden) had made ELISpot kits available in a 100-plate format. Pre-coated plates are also included to save time and reduce assay variability. In 2022, The company also made available the Human IL-21 analyte in two colors in its FluoroSpot Flex platform.
- In 2021, The company Cellular Technology Limited (CTL) (US) launched ImmunoSpot kits that contain precoating quality controlled (PCQC) plates, thereby adding an essential audit trail to ELISPOT analysis.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com